In a nutshell The study evaluated the link between statin (cholesterol-lowering drugs) use and risks of breast cancer (BC) relapse under adjuvant aromatase inhibitors (AI) therapy in women after their menopause. The main finding was that statin use was related with lower risks of BC relapse in such patients. Some background Women with...Read More
Confined or spread disease-Spread to regional lymph nodes Posts on Medivizor
Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?
In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...Read More
How common are allergic reactions to different biological therapies in patients with advanced melanoma?
In a nutshell This study compared the frequency of allergic reactions to different doses of three biological therapies in patients with advanced melanoma. The authors found that different doses of the three drugs reduced the number of allergic reactions. Some background Biological therapy has significantly improved treatment results for patients...Read More
In a nutshell This study looked at fertility preservation (FP) in patients with breast cancer. It found that many patients choose FP before chemotherapy and that most patients have a return of ovulation following treatment. Some background 12% of patients newly diagnosed with breast cancer are under 40 years of age. Preserving fertility is a concern...Read More
Does it matter how much healthy tissue is removed during surgery for patients with breast cancer who received chemotherapy first?
In a nutshell This study examined if there was a difference in patients with breast cancer first treated with chemotherapy that had a wide or narrow margin of healthy tissue removed during surgery. The results showed that the outcomes were similar regardless of how much healthy tissue was removed. Some background Traditionally, mastectomy (the...Read More
Long-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer
In a nutshell This study looked at whether pertuzumab (Perjeta) benefits patients with metastatic HER2-positive breast cancer when added to trastuzumab (Herceptin) and docetaxel (Taxotere) treatment. They found that adding pertuzumab improved long-term patient outcomes. Some background Breast cancer can now be tested for some of the signals involved...Read More
In a nutshell This study aimed to investigate the effectiveness and safety of atezolizumab plus nab-paclitaxel in unresectable, locally advanced or metastatic triple-negative breast cancer. This study concluded that this combination had a benefit in patients with PD-L1 immune cell positive...Read More
Palbociclib and exemestane versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer
In a nutshell This study aimed to compare the safety and effectiveness of palbociclib and endocrine therapy to capecitabine chemotherapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. This study concluded that palbociclib and endocrine therapy is more effective than...Read More
In a nutshell This article reviewed treatment options for patients with advanced melanoma. Some background Treatment for melanoma depends on several factors, including the disease stage. Advanced melanoma is diagnosed when cancer can be detected outside of the original tumor. This makes treatment difficult. Currently, there...Read More
In a nutshell This article reviewed different treatment options for patients with melanoma. Some background Melanoma is one of the most common cancers worldwide. Treatment options for patients with melanoma depend on how extensive it is. Melanoma that remains in its original site in the skin is called localized disease. It can also...Read More
In a nutshell This study aimed to compare the outcomes for patients with early breast cancer who received 6- or 12-months trastuzumab after surgery. This study concluded that the standard duration of trastuzumab after surgery should remain 12 months. Some background Trastuzumab (Herceptin) is a targeted...Read More
In a nutshell This study compared hormone therapy and chemotherapy for the treatment of metastatic (cancer that has spread) breast cancer. The authors concluded that hormone therapy plus targeted therapy is better than chemotherapy for patients with metastatic breast cancer. Some background Different types of breast cancer have different receptors....Read More